Clinical Investigation of NMS Assist
Primary Purpose
Parkinson
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
NMS Assist
Sponsored by
About this trial
This is an interventional supportive care trial for Parkinson focused on measuring Parkinson Disease, Self-Management, Telemedicine
Eligibility Criteria
Inclusion Criteria:
- Willing and able to provide informed consent and comply with intervention requirements
- 18 years or older
- Be fluent in English
- Not resident in a care or nursing home
- Ambulant
- Have compatible smartphone/data access
- Normally under the care of the Parkinson's service in the participating organisation
- Participant's HCP in the participating organisation consented to participate in the study
Exclusion Criteria:
- Secondary cause of parkinsonism
- Significant cognitive impairment or a diagnosis of Parkinson's disease dementia
- Living in residential care facilities
- Previous involvement in development or testing of the NMS Assist system
- Significant comorbidity, which in the opinion of the chief investigator would preclude safe participation in the study or protocol compliance (e.g. life expectancy <6 months)
- In a dependent/unequal relationship with anyone involved in the research or care teams
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
NMS Assist
Arm Description
NMS Assist provides a system of linking PwP, CPs, and healthcare providers (HCPs) to monitor and empower self-management of non-motor symptoms through the use of a mobile app and web portal.
Outcomes
Primary Outcome Measures
Patient (and care partner) activation
Patient Activation Measure (and caregiver version) will be used to evaluate their confidence, knowledge, and skills at non-motor symptom self-management
Secondary Outcome Measures
Presence of non-motor symptoms
Measured using the Non-Motor Symptoms Questionnaire (NMSQ), patients tick 'yes' or 'no' for each symptom listed
Frequency and severity of non-motor symptoms
Measured using the Movement Disorder Society Non-Motor Symptoms Scale (MDS-NMS), where higher scores indicate greater frequency and/or severity
Short-form self-assessment of functioning and well-being related to Parkinson's disease
Measured using the short-form Parkinson's Disease Questionnaire (PDQ-8), patients indicate the frequency with which they experience certain issues
Long-form self-assessment of functioning and well-being related to Parkinson's disease
Measured using the long-form Parkinson's Disease Questionnaire PDQ-39, patients indicate the frequency with which they experience certain issues
Carer well-being and quality of life
Measured using the Parkinson Disease Questionnaire for care partners; care partners indicate the frequency with which they experience certain issues
Health status
Measured using the EQ-5D-5L; higher scores on the EQ-5D-5L descriptive system indicate worse health problems in the specific dimension whereas a high score in the EQ VAS indicates better health on the day of the questionnaire
Mental well-being
Measured using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS); Scores range from 14 to 70 (on the 14 item version) and higher scores indicate greater positive mental wellbeing
Adverse events
Adverse Event Reporting
Clinical safety
Record of any events missed
Healthcare contacts
Number of PwP-initiated contacts with healthcare team (through the 'request healthcare contact' feature) and the number of HCP-initiated contacts (due to system flagging PwP based on PwP and CP-reported outcomes), recorded by the system
Technical and implementation issues
Technical issues identified from the system use data and by participants and process measures relating to service delivery
Quantitative usability
System Usability Scale, out of 100 with higher scores indicating better usability
Acceptability
Acceptability and usability feedback from semi-structured interviews
System use and compliance
Data collected via the system about users engagement with the system (e.g. number of times accessed, length of time accessed, features used)
Engagement
Qualitative feedback from participants
Costs
Cost analysis will be used to examine the factors impacting costs for implementing the system
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05414071
Brief Title
Clinical Investigation of NMS Assist
Official Title
The Impact of a Digital Artificial Intelligence System on the Monitoring and Self-management of Non-motor Symptoms in People With Parkinson's
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 1, 2023 (Anticipated)
Primary Completion Date
March 1, 2025 (Anticipated)
Study Completion Date
March 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Plymouth
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Parkinson's can cause a wide range of non-motor symptoms (NMS), including pain and problems with mental health, memory and sleep. These affect the quality of life of people with Parkinson's (PwP) and their care partners (CP). If these issues are not recognised and managed quickly, they can result in escalating problems. Many PwP are unsure of the extent and variety of the NMS and how simple adjustments at home could improve them. We have developed a digital system, NMS Assist, to help PwP monitor their non-motor symptoms and develop skills to self-manage them.
Such a tool needs to be simple to use, safe and effective. We will ask 60 PwP, CP and members of their Parkinson's healthcare team to use NMS Assist for 12 months, and we will monitor how they use the tool. PwP and CPs will be asked if they feel more knowledgeable and confident to manage their own symptoms whilst being better able to discuss a problem with their healthcare professional.
A smaller group of the participants will discuss their experiences in more detail to help pinpoint aspects that work well and those needing adjustment and development. Members of the healthcare team will be asked to assess any improvement in communication with PwP and CPs.
It is thought that the use of this system will result in improved quality of life and increased knowledge and confidence for managing symptoms while safely reducing the time spent by health care professionals on manageable non-motor symptoms.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson
Keywords
Parkinson Disease, Self-Management, Telemedicine
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
NMS Assist
Arm Type
Experimental
Arm Description
NMS Assist provides a system of linking PwP, CPs, and healthcare providers (HCPs) to monitor and empower self-management of non-motor symptoms through the use of a mobile app and web portal.
Intervention Type
Device
Intervention Name(s)
NMS Assist
Intervention Description
The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
Primary Outcome Measure Information:
Title
Patient (and care partner) activation
Description
Patient Activation Measure (and caregiver version) will be used to evaluate their confidence, knowledge, and skills at non-motor symptom self-management
Time Frame
Assessed monthly for 12 months
Secondary Outcome Measure Information:
Title
Presence of non-motor symptoms
Description
Measured using the Non-Motor Symptoms Questionnaire (NMSQ), patients tick 'yes' or 'no' for each symptom listed
Time Frame
Measured at patients' discretion throughout intervention (12 months)
Title
Frequency and severity of non-motor symptoms
Description
Measured using the Movement Disorder Society Non-Motor Symptoms Scale (MDS-NMS), where higher scores indicate greater frequency and/or severity
Time Frame
Measured at baseline, 6, and 12 months
Title
Short-form self-assessment of functioning and well-being related to Parkinson's disease
Description
Measured using the short-form Parkinson's Disease Questionnaire (PDQ-8), patients indicate the frequency with which they experience certain issues
Time Frame
Measured at patients' discretion throughout intervention (12 months)
Title
Long-form self-assessment of functioning and well-being related to Parkinson's disease
Description
Measured using the long-form Parkinson's Disease Questionnaire PDQ-39, patients indicate the frequency with which they experience certain issues
Time Frame
Measured at baseline, 6, and 12 months
Title
Carer well-being and quality of life
Description
Measured using the Parkinson Disease Questionnaire for care partners; care partners indicate the frequency with which they experience certain issues
Time Frame
Measured at care partners' discretion throughout intervention (12 months)
Title
Health status
Description
Measured using the EQ-5D-5L; higher scores on the EQ-5D-5L descriptive system indicate worse health problems in the specific dimension whereas a high score in the EQ VAS indicates better health on the day of the questionnaire
Time Frame
Measured at baseline, 6, and 12 months
Title
Mental well-being
Description
Measured using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS); Scores range from 14 to 70 (on the 14 item version) and higher scores indicate greater positive mental wellbeing
Time Frame
Measured at baseline, 6, and 12 months
Title
Adverse events
Description
Adverse Event Reporting
Time Frame
Throughout 12 months
Title
Clinical safety
Description
Record of any events missed
Time Frame
Throughout 12 months
Title
Healthcare contacts
Description
Number of PwP-initiated contacts with healthcare team (through the 'request healthcare contact' feature) and the number of HCP-initiated contacts (due to system flagging PwP based on PwP and CP-reported outcomes), recorded by the system
Time Frame
Throughout 12 months
Title
Technical and implementation issues
Description
Technical issues identified from the system use data and by participants and process measures relating to service delivery
Time Frame
Throughout 12 months
Title
Quantitative usability
Description
System Usability Scale, out of 100 with higher scores indicating better usability
Time Frame
6 and 12 months
Title
Acceptability
Description
Acceptability and usability feedback from semi-structured interviews
Time Frame
3, 6, and 12 months
Title
System use and compliance
Description
Data collected via the system about users engagement with the system (e.g. number of times accessed, length of time accessed, features used)
Time Frame
Throughout 12 months
Title
Engagement
Description
Qualitative feedback from participants
Time Frame
3, 6, and 12 months
Title
Costs
Description
Cost analysis will be used to examine the factors impacting costs for implementing the system
Time Frame
Throughout 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Willing and able to provide informed consent and comply with intervention requirements
18 years or older
Be fluent in English
Not resident in a care or nursing home
Ambulant
Have compatible smartphone/data access
Normally under the care of the Parkinson's service in the participating organisation
Participant's HCP in the participating organisation consented to participate in the study
Exclusion Criteria:
Secondary cause of parkinsonism
Significant cognitive impairment or a diagnosis of Parkinson's disease dementia
Living in residential care facilities
Previous involvement in development or testing of the NMS Assist system
Significant comorbidity, which in the opinion of the chief investigator would preclude safe participation in the study or protocol compliance (e.g. life expectancy <6 months)
In a dependent/unequal relationship with anyone involved in the research or care teams
12. IPD Sharing Statement
Plan to Share IPD
Undecided
IPD Sharing Plan Description
Data belongs to the study sponsor (the University of Plymouth) and deidentified data will be made available in line with the data sharing policy developed with Parkinson's UK and PPI representatives.
Citations:
PubMed Identifier
36155396
Citation
Meinert E, Milne-Ives M, Chaudhuri KR, Harding T, Whipps J, Whipps S, Carroll C. The Impact of a Digital Artificial Intelligence System on the Monitoring and Self-management of Nonmotor Symptoms in People With Parkinson Disease: Proposal for a Phase 1 Implementation Study. JMIR Res Protoc. 2022 Sep 26;11(9):e40317. doi: 10.2196/40317.
Results Reference
derived
Learn more about this trial
Clinical Investigation of NMS Assist
We'll reach out to this number within 24 hrs